Arcturus Therapeutics price target raised to $45 from $35 at Wells Fargo

Wells Fargo analyst Jim Birchenough raised the firm’s price target on Arcturus Therapeutics (ARCT) to $45 from $35 and keeps an Overweight rating on the shares. Following review of data from the Japan booster study, the firm points out on a research note on Friday that ARCT-154 demonstrates superiority over Pfizer’s (PFE) COMIRNATY, which in its opinion establishes Arcturus’ mRNA vaccine platform as a strong contender with differentiation in longer durability.